

Intestinal Ultrasound in Crohn's Disease: What is your diagnosis?

Michael W. Winter, MD

Dartmouth Hitchcock Medical Center, Lebanon NH USA


IBUS Advanced Ultrasound Workshop – Module 3 DDW, San Diego, US, May 5th, 2025



Disclosure

- Advisory Boards:
 - AbbVie
 - Bristol Myers Squibb
- Consultant:
 - Dynamed

- 12 year old referred for 1-month of changed bowel habits
- Loose stool, 3-4 episodes daily, hematochezia
- Also endorses fatigue, generalized abdominal pain, subjective fevers, oral ulcers and diffuse joint pains
- Shigella stool test (+); fecal calprotectin >3000 ug/g
- Hemoglobin normal, MCV 75 (low), CRP 7.9 mg/dL, ESR 80 mm/hr






2D G50/DR32/FA10/P90/Frq Gen./3.5cm Terminal Ileum Tr 2D G50/DR32/FA10/P90/Frq Gen./3.5cm C G60/0.77kHz/F1/FA8 S. O.



Index endoscopy









Next steps

• Planned for exclusive enteral nutrition, not tolerated

Transitioned to the Crohn's disease exclusion diet

Shortly after initiated treatment with adalimumab












Colonoscopy 1-year from diagnosis














Terminal Ileum Terminal Ileum



Additional testing

Normal MR enterography

Normal small bowel follow through

What next?



Next steps

- Exploratory laparoscopy
 - 2-3 cm stricture seen 20-cm from the ileocecal valve
 - 1-2 cm focal stricture seen in the mid-ileum
 - Both resected




Case 2

- 42 year old F with a history of BRCA-1 gene s/p preventative total abdominal hysterectomy and bilateral salpingo-oophorectomy and Crohn's colitis diagnosed in 1995 presents with diarrhea, hematochezia, tenesmus and urgency
- Prior Crohn's disease therapies:
 - Mesalamine, 6-mercaptopurine, infliximab, adalimumab, natalizumab (discontinued with positive JC virus)
- On vedolizumab when presented with flare
- Notable labs:
 - C-reactive protein 373 mg/L on presentation
 - C-reactive protein 280 mg/L after 72-hours IV methylprednisolone (day 3)
 - C-reactive protein 94 mg/L after IV methylprednisolone 40 mg, upadacitinib 45 mg PO daily and Crohn's disease exclusion diet (day 14)




Flexible sigmoidoscopy on admission



IUS, 1-week on phase 1 CDED, upadacitinib and methylprednisolone












IUS, 3-weeks: phase 1 CDED, upadacitinib, prednisone 30 mg PO daily





IUS, 5-weeks: phase 2 CDED, upadacitinib, prednisone 15 mg PO daily





IUS Pearls in Crohn's Disease

- Increase predictive value in endoscopic procedures
 - Not a substitute, but can help prioritize
- Useful for medication efficacy assessment: short and long term
- Dynamic study, provides "different" perspective on strictures, inflammation, and fibrosis
 - Work to be done here, but consider IUS an additional tool
 - Use in combination to clinical assessment, cross-sectional imaging and endoscopy



Many thanks

- Mallory Chavannes, MD Children's Hospital Los Angeles
- Rishika Chugh, MD University of California at San Francisco